NO944476L - Tetrahydro- and perhydro-isoquinoline derivatives and therapeutic agents containing them - Google Patents
Tetrahydro- and perhydro-isoquinoline derivatives and therapeutic agents containing themInfo
- Publication number
- NO944476L NO944476L NO944476A NO944476A NO944476L NO 944476 L NO944476 L NO 944476L NO 944476 A NO944476 A NO 944476A NO 944476 A NO944476 A NO 944476A NO 944476 L NO944476 L NO 944476L
- Authority
- NO
- Norway
- Prior art keywords
- group
- nwr2
- carbon atoms
- general formula
- contain
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Legemiddel for peroral anvendelse, hvilket som virkestoff ved siden av vanlige galeniske hjelpemidler pr. enkeltdose inne- holder 10 til 1.000 mg av en forbindelse med den generelle formel I eller II NWR2 NWR2 hvori: W betyr en karbonylgruppe eller en enkeltbinding; R1 et hydrogenatom eller en gruppe med den generelle formel R3CO, hvori R3 står for en laverealkyl-, laverealkoksy-, monolaverealkylamino- eller dilaverealkylaminogruppe; R2 en alkylrest med 3 til 20 karbonatomer som er forgrenet eller rettkjedet, og inneholder l til 3 dobbeltbindinger, kan inneholde en mettet cyklus med 3 til 7 karbonatomer integrert i kjeden, eller som substituent, kan være sub- stituert med en eller flere aromatiske ringer eller inne- holde et oksygen- eller svovelatom, som racemat såvel som isolerte enantiomere, eller deres addisjonssalt med en fysiologisk fordragelig syre, samt virkestoffene selv, i den utstrekning de er nye.Oral use drug, which acts as an active ingredient in addition to the usual galenic aids. single dose contains 10 to 1,000 mg of a compound of the general formula I or II NWR2 NWR2 wherein: W means a carbonyl group or a single bond; R1 is a hydrogen atom or group of the general formula R3CO wherein R3 represents a lower alkyl, lower alkoxy, monolaverealkylamino or dilaveralkylamino group; R2 an alkyl residue having 3 to 20 carbon atoms branched or straight chain, containing 1 to 3 double bonds, may contain a saturated cycle of 3 to 7 carbon atoms integrated into the chain, or as a substituent, may be substituted by one or more aromatic rings or contain an oxygen or sulfur atom, such as racemates as well as isolated enantiomers, or their addition salt with a physiologically tolerable acid, as well as the active substances themselves, to the extent that they are new.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4216942A DE4216942A1 (en) | 1992-05-22 | 1992-05-22 | Tetrahydro and perhydroisoquinoline derivatives and therapeutic agents containing them |
| PCT/EP1993/001197 WO1993024461A1 (en) | 1992-05-22 | 1993-05-13 | Tetrahydro and perhydro isoquinolin derivatives and therapeutic agents containing them |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO944476D0 NO944476D0 (en) | 1994-11-22 |
| NO944476L true NO944476L (en) | 1994-12-09 |
Family
ID=25915061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO944476A NO944476L (en) | 1992-05-22 | 1994-11-22 | Tetrahydro- and perhydro-isoquinoline derivatives and therapeutic agents containing them |
Country Status (1)
| Country | Link |
|---|---|
| NO (1) | NO944476L (en) |
-
1994
- 1994-11-22 NO NO944476A patent/NO944476L/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO944476D0 (en) | 1994-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP9701039A0 (en) | Derivatives of 2- (2-oxo-ethlidene)-imidazolidin-4-one. | |
| GT199900139A (en) | DERIVATIVES OF QUINOLIN-2-ONA ÙTILES AS AGENTS AGAINST CANCER. | |
| TW375615B (en) | Galanthamine derivatives and their use as medicaments | |
| MA26861A1 (en) | NON-PEPTIDIC INHIBITORS OF VLA-4 DEPENDENCY OF CELL BINDING USEFUL IN THE TREATMENT OF INFLAMMATORY, AUTOIMMUNE AND RESPIRATORY DISEASES | |
| CA2318349A1 (en) | Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use | |
| DE3789967T2 (en) | USE OF MONOAMINE ACIDES IN CHOLINERGENIC NERVOUS SYSTEM DEFICIENCIES. | |
| MY105402A (en) | 17-beta-substituted-4-aza-5alpha-androstan-3-one derivatives and process for their preparation. | |
| WO2000021927A3 (en) | Pyrrole-2,5-diones as gsk-3 inhibitors | |
| BG104998A (en) | Isothiazole derivatives useful as anticancer agents | |
| UA27238C2 (en) | Indoline derivatives, their pharmaceutical acceptable salts which are antagonists of vasopressin vi-receptors, method for their synthesis, intermediate compounds and pharmaceutical composition | |
| MA27582A1 (en) | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | |
| IL104090A (en) | Phosphonosuccinic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing these compounds | |
| DK0928788T3 (en) | Imidazolidin-4-one derivatives useful as anticancer agents | |
| HK1010881A1 (en) | Derivatives of azetidine and pyrrolidine | |
| DE69132713D1 (en) | Benzylidenthiazolidine derivatives, their preparation and their use as lipid peroxide inhibitors | |
| NO20053483L (en) | 4-Anilinoquinazoline derivatives for the treatment of abnormal cell growth | |
| HU9301155D0 (en) | Methods for producing steroide derivatives and for their application in medical treatment | |
| NO975901L (en) | Vinyl pyrrolidinone cephalosporins with basic substituents | |
| EA200101077A1 (en) | COMPOSITION FOR PREVENTION OR TREATMENT OF WEAKNESS, INCLUDING A HYDROXICORIC ACID DERIVATIVE OR EXTRACT OF ANGELICAE GENERA PLANT, CONTAINING IT | |
| NO984761L (en) | Aminoisoquinolines and aminotienopyridine derivatives and their use as anti-inflammatory agents | |
| CA2321188A1 (en) | Derivatives of azetidine and pyrrolidine | |
| HU9203189D0 (en) | New 17beta-substituted aza-androstane derivatives | |
| MY129176A (en) | Tetrahydro gamma-carbolines | |
| BG103426A (en) | Derivatives of substituted 4-biphenyl-4-hydroxy-oil acids as inhibitors of matrix metalloproteases | |
| DK0780125T3 (en) | Use of hydantoin derivatives for the manufacture of a medicament for the treatment of diseases associated with the presence of active oxygen and free radicals |